Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Akebia Therapeutics (NASDAQ: AKBA): Vafseo's Growth Against Auryxia's Decline

Akebia Therapeutics is a biopharmaceutical company focused on kidney disease, listed on theNasdaqunder AKBA. Its commercial portfolio is anchored by Vafseo (vadadustat), an oral HIF-PH inhibitor for anemia due to chronic kidney disease in adults on dialysis, alongside Auryxia, an established phosphate-binder product now …

Nitish Kishor | 10 September 2026

Upstream Bio (NASDAQ: UPB): Verekitug Moves Into Pivotal Phase 3 Testing

Upstream Bio is developing verekitug, a monoclonal antibody that blocks the receptor for thymic stromal lymphopoietin (TSLP), an upstream driver of inflammation implicated across respiratory disease. On September 1, 2026, the company announced pivotal Phase 3 development plans for verekitug in both severe asthma …

Nitish Kishor | 10 September 2026

America Great Health (OTC: AAGH): A Profile of the Sub-Penny Biotech Micro-Cap

America Great Health describes itself as a biotechnology company focused on theResearch and Developmentof protein and peptide small-molecule drugs, alongside interests spanning AI-based diagnostic devices, cell therapy and regenerative medicine. The company is based in Alhambra, California, and was formerly known as Crown Marketing …

Nitish Kishor | 10 September 2026

Nascent Biotech (OTC: NBIO): Pritumumab's Status as a Clinical-Stage Antibody

Nascent Biotech is a clinical-stage biopharmaceutical company developing Pritumumab, a natural human monoclonal antibody. The company has positioned Pritumumab as a treatment candidate for brain cancers such as glioblastoma, as well as epithelial cancers including lung, breast, colon and pancreatic tumors. Its most recent …

Nitish Kishor | 10 September 2026

Acura Pharmaceuticals (OTC: ACUR): The State of the Abuse-Deterrent Drug Developer

Acura is a drug-delivery company built around abuse-deterrent pharmaceutical technologies, including its Aversion and LIMITx platforms designed to reduce the potential for misuse of oral medications. Its portfolio has included Oxaydo, an immediate-release oxycodone product, and the Nexafed line of pseudoephedrine-based cold and allergy …

Nitish Kishor | 10 September 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX): Positive Phase 3 Data in Psoriatic Arthritis

MoonLake is a clinical-stage biopharmaceutical company developing sonelokimab, a Nanobody designed to inhibit IL-17A and IL-17F, cytokines central to inflammatory disease. On August 10, 2026, the company announced positive topline results from its Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis (PsA), reporting …

Nitish Kishor | 10 September 2026

Yubo International Biotech (OTC: YBGJ): A Profile of the China-Focused Stem-Cell Company

Yubo International Biotech is a China-focused health and personal-care company built around endometrial stem-cell research, development and application. It markets consumer and wellness products under the VIVCELL brand, spanning respiratory, skincare, hair-care and beverage lines, and offers stem-cell testing and health-management consulting services. The …

Nitish Kishor | 10 September 2026

Seres Therapeutics (NASDAQ: MCRB): Balancing SER-155 Data With a Tight Cash Position

Seres Therapeutics is a Nasdaq-listed clinical-stage company pioneering microbiome therapeutics, live bacterial consortia designed to treat disease by modulating the gut. Its former commercial product, VOWST, was divested to Nestlé Health Science, and Seres now centers its future on SER-155, a cultivated microbiome candidate. …

Nitish Kishor | 10 September 2026

Eco-Growth Strategies (OTC: ECGS): Bottled Water Comeback and Uplisting Plans

Eco-Growth Strategies is a Hawaii-basedBusinessnow centered on premium bottled water production and distribution, having historically described itself as a provider of design-build infrastructure services, including telecommunications work. The company trades on the U.S. over-the-counter market, not a national exchange. Through 2026 it has publicized …

Nitish Kishor | 10 September 2026

Change Agents Corporation (NASDAQ: CHGA): Inside the Company's Reverse Stock Split

Change Agents Corporation is a developer of agentic artificial-intelligence software aimed at small businesses and content creators. Its products include Beacon, described as an AI search-optimization platform, and Catch-Up, an autonomous content-creation tool, both offered through a software-as-a-service model. The company also distributes KetoAir, …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…